CD8A and cancer: Even though the PI3K/AKT pathway plays such a central role in effector T cell biology, the impact of p110δ inhibitors on cancer immunity has historically been associated solely with the promotion of effector CD8+ T cells due to ablating regulatory T cells (Tregs) after systemic drug administration (19).